Head-to-head · WeighScore
Beluga Health vs Tell Her Doc
The verdict
Tell Her Doc takes it — 57.2/100 to 55.8/100, but only just.
Tell Her Doc grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Tell Her Doc is a women-focused, self-pay telehealth program for compounded GLP-1 weight loss — compounded semaglutide and tirzepatide in injection, oral, and orally-dissolving-tablet forms, plus microdoses. Beluga Health is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Beluga Health | Tell Her Doc |
|---|---|---|
| WeighScore | 55.8/100 | 57.2/100 |
| Grade | C | C |
| Scorecard rank | #431 | #404 |
| Semaglutide | Not disclosed | $269/mo (microdose tier, plus a separate fee, compounded) |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #431 · C
Strengths
- Supports GLP-1 care with compounded semaglutide and tirzepatide
- Board-certified providers and a 50-state medical infrastructure
- LegitScript certified with SOC 2 and ISO 27001 security
- Pharmacies follow FDA/USP standards with third-party batch testing
- Powers many DTC brands as a turnkey telehealth backbone
Where it loses points
- White-label B2B group, not a direct consumer-facing service
- Offers compounded, not FDA-approved branded, GLP-1s
- No public consumer pricing for the GLP-1 offering
- Cited among nationwide groups tied to FDA telehealth GLP-1 scrutiny
- Care quality varies by the consumer brand using the platform
Graded #404 · C
Strengths
- Full compounded GLP-1 lineup — semaglutide and tirzepatide in injection, oral and orally-dissolving-tablet forms, plus microdoses
- Names its compounding pharmacy partner (Casa Pharma RX), which is independently listed in our pharmacy registry
- No monthly membership, cancel anytime, free discreet shipping; HSA/FSA eligible with buy-now-pay-later plans
- Serves patients in all 50 states via a private online consultation
Where it loses points
- 'All sales are final' — no refunds once medication has left the pharmacy
- Exact price is plan-dependent, shown after you pick a product; advertised 'starting at $269', with a lower $140 intro on oral semaglutide
- References LegitScript but without an independently verifiable seal — we couldn't confirm certification
- Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
- Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.